Spinal malignant triton tumor in a patient with neurofibromatosis type 1

References (9)

1. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178:1932-9
2. Engel EE, Brassesco MS, Valera ET, Barbosa MHN,Yamashita MEAS, Scrideli CA, et al. Clinico-genetic aspects of a pediatric non-neurofibromatosis type 1 malignant triton tumor with loss of chromosome X. Pediatr Blood Cancer 2012;59:1320-3
3. Kamran SC, Howard SA, Shinagare AB, Krajewski KM. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. EJSO 2013;39:46-52
4. McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012;106:51-6
5. Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 2007;20:135-41
6. Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012;19:878-85
7. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97:340-9
8. Ferner RE, Gutmann DG. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 2002;62:1573-7
9. Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 2011;34:417-21.